EGFR and non-small cell lung carcinoma: The clinical data of 10 patients with advanced NSCLC who survived for >5 years were retrospectively reviewed, and a good PS, adenocarcinoma, and a history of EGFR-TKI administration were the factors contributing to long-term survival.[4] According to another retrospective study,[3] 20 of 137 patients with EGFR-mutant lung adenocarcinoma survived for ≥5 years, and exon 19 deletion, absence of extrathoracic metastases, absence of brain metastasis, and current non-smoking status were reportedly good prognostic factors.